Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines

NCT02985398 is registered in ClinicalTrials.gov with Alder Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT02985398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02985398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
Lead sponsor
Alder Biopharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2016
Completion date
March 31, 2019
Enrollment
128 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

migraine disorder